The impact of sedative and vasopressor agents on cerebrovascular reactivity in severe traumatic brain injury.
Autoregulation
Cerebrovascular reactivity
Sedative drugs
Vasopressors
Journal
Intensive care medicine experimental
ISSN: 2197-425X
Titre abrégé: Intensive Care Med Exp
Pays: Germany
ID NLM: 101645149
Informations de publication
Date de publication:
05 Aug 2023
05 Aug 2023
Historique:
received:
24
01
2023
accepted:
17
05
2023
medline:
5
8
2023
pubmed:
5
8
2023
entrez:
4
8
2023
Statut:
epublish
Résumé
The aim of this study is to evaluate the impact of commonly administered sedatives (Propofol, Alfentanil, Fentanyl, and Midazolam) and vasopressor (Dobutamine, Ephedrine, Noradrenaline and Vasopressin) agents on cerebrovascular reactivity in moderate/severe TBI patients. Cerebrovascular reactivity, as a surrogate for cerebral autoregulation was assessed using the long pressure reactivity index (LPRx). We evaluated the data in two phases, first we assessed the minute-by-minute data relationships between different dosing amounts of continuous infusion agents and physiological variables using boxplots, multiple linear regression and ANOVA. Next, we assessed the relationship between continuous/bolus infusion agents and physiological variables, assessing pre-/post- dose of medication change in physiology using a Wilcoxon signed-ranked test. Finally, we evaluated sub-groups of data for each individual dose change per medication, focusing on key physiological thresholds and demographics. Of the 475 patients with an average stay of 10 days resulting in over 3000 days of recorded information 367 (77.3%) were male with a median Glasgow coma score of 7 (4-9). The results of this retrospective observational study confirmed that the infusion of most administered agents do not impact cerebrovascular reactivity, which is confirmed by the multiple linear regression components having p value > 0.05. Incremental dose changes or bolus doses in these medications in general do not lead to significant changes in cerebrovascular reactivity (confirm by Wilcoxon signed-ranked p value > 0.05 for nearly all assessed relationships). Within the sub-group analysis that separated the data based on LPRx pre-dose, a significance between pre-/post-drug change in LPRx was seen, however this may be more of a result from patient state than drug impact. Overall, this study indicates that commonly administered agents with incremental dosing changes have no clinically significant influence on cerebrovascular reactivity in TBI (nor do they impair cerebrovascular reactivity). Though further investigation in a larger and more diverse TBI patient population is required.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study is to evaluate the impact of commonly administered sedatives (Propofol, Alfentanil, Fentanyl, and Midazolam) and vasopressor (Dobutamine, Ephedrine, Noradrenaline and Vasopressin) agents on cerebrovascular reactivity in moderate/severe TBI patients. Cerebrovascular reactivity, as a surrogate for cerebral autoregulation was assessed using the long pressure reactivity index (LPRx). We evaluated the data in two phases, first we assessed the minute-by-minute data relationships between different dosing amounts of continuous infusion agents and physiological variables using boxplots, multiple linear regression and ANOVA. Next, we assessed the relationship between continuous/bolus infusion agents and physiological variables, assessing pre-/post- dose of medication change in physiology using a Wilcoxon signed-ranked test. Finally, we evaluated sub-groups of data for each individual dose change per medication, focusing on key physiological thresholds and demographics.
RESULTS
RESULTS
Of the 475 patients with an average stay of 10 days resulting in over 3000 days of recorded information 367 (77.3%) were male with a median Glasgow coma score of 7 (4-9). The results of this retrospective observational study confirmed that the infusion of most administered agents do not impact cerebrovascular reactivity, which is confirmed by the multiple linear regression components having p value > 0.05. Incremental dose changes or bolus doses in these medications in general do not lead to significant changes in cerebrovascular reactivity (confirm by Wilcoxon signed-ranked p value > 0.05 for nearly all assessed relationships). Within the sub-group analysis that separated the data based on LPRx pre-dose, a significance between pre-/post-drug change in LPRx was seen, however this may be more of a result from patient state than drug impact.
CONCLUSIONS
CONCLUSIONS
Overall, this study indicates that commonly administered agents with incremental dosing changes have no clinically significant influence on cerebrovascular reactivity in TBI (nor do they impair cerebrovascular reactivity). Though further investigation in a larger and more diverse TBI patient population is required.
Identifiants
pubmed: 37541993
doi: 10.1186/s40635-023-00524-4
pii: 10.1186/s40635-023-00524-4
pmc: PMC10403459
doi:
Types de publication
Journal Article
Langues
eng
Pagination
54Subventions
Organisme : Natural Sciences and Engineering Research Council of Canada
ID : DGECR-2022-00260
Organisme : Natural Sciences and Engineering Research Council of Canada
ID : RGPIN-2022-03621
Organisme : Natural Sciences and Engineering Research Council of Canada
ID : ALLRP-576386-22
Informations de copyright
© 2023. European Society of Intensive Care Medicine and Springer Nature Switzerland AG.
Références
Anesth Analg. 2003 Aug;97(2):572-576
pubmed: 12873955
Neurosurgery. 2015 Jan;76(1):67-80
pubmed: 25525693
J Clin Monit Comput. 2020 Oct;34(5):971-994
pubmed: 31573056
Neurotrauma Rep. 2020 Oct 13;1(1):100-112
pubmed: 33251530
Acta Neurochir (Wien). 2018 Dec;160(12):2277-2287
pubmed: 30251196
Crit Care Explor. 2022 Mar 04;4(3):e0656
pubmed: 35265854
J Neurosurg Anesthesiol. 2016 Apr;28(2):123-40
pubmed: 26465642
Acta Physiol (Oxf). 2021 Jul;232(3):e13672
pubmed: 33978309
Acta Neurochir Suppl. 2016;122:245-8
pubmed: 27165915
Nephrol Dial Transplant. 2013 Aug;28(8):2058-65
pubmed: 23615760
Cancers (Basel). 2017 Oct 25;9(11):
pubmed: 29068364
Neurosurgery. 2017 Jan 01;80(1):6-15
pubmed: 27654000
J Neurotrauma. 2018 Dec 1;35(23):2812-2819
pubmed: 29808745
Acta Neurochir Suppl. 2005;95:25-8
pubmed: 16463814
Acta Neurochir (Wien). 2019 Sep;161(9):1955-1964
pubmed: 31240583
Front Netw Physiol. 2022 Feb 16;2:837860
pubmed: 36926091
Neurosurgery. 2012 Sep;71(3):652-60; discussion 660-1
pubmed: 22653390
Crit Care. 2016 May 05;20(1):128
pubmed: 27145814
Neurocrit Care. 2020 Oct;33(2):542-551
pubmed: 32056131
J Neurotrauma. 2021 Oct 15;38(20):2790-2800
pubmed: 34407385
Intensive Care Med Exp. 2022 Aug 13;10(1):33
pubmed: 35962913
Neurotrauma Rep. 2021 Dec 20;2(1):639-659
pubmed: 35018365
Acta Neurochir (Wien). 2020 Nov;162(11):2683-2693
pubmed: 32959342
Intensive Care Med. 2019 Dec;45(12):1783-1794
pubmed: 31659383
Neurotrauma Rep. 2021 Nov 09;2(1):488-501
pubmed: 34901944
Neurocrit Care. 2021 Feb;34(1):325-335
pubmed: 32468328
Intensive Care Med. 2020 May;46(5):919-929
pubmed: 31965267
J Neurotrauma. 2023 Jun;40(11-12):1098-1111
pubmed: 36047825
J Neurotrauma. 2020 Sep 1;37(17):1854-1863
pubmed: 32253987
Crit Care Med. 2015 Sep;43(9):1952-63
pubmed: 26154931
J Neurotrauma. 2014 Nov 15;31(22):1872-80
pubmed: 24915462
J Neurosurg Anesthesiol. 2011 Oct;23(4):358-62
pubmed: 21908989
Br J Anaesth. 1993 Aug;71(2):267-71
pubmed: 8123405
J Neurosurg. 2015 Mar;122(3):588-94
pubmed: 25423266
Crit Care Med. 2017 Sep;45(9):1464-1471
pubmed: 28816837
J Neurotrauma. 2018 May 15;35(10):1107-1115
pubmed: 29241396
Acta Neurochir (Wien). 2011 Nov;153(11):2189-95
pubmed: 21909998
Neurosurgery. 1997 Jul;41(1):11-7; discussion 17-9
pubmed: 9218290
J Neurotrauma. 2020 May 15;37(10):1233-1241
pubmed: 31760893
Anaesth Intensive Care. 2012 Nov;40(6):949-57
pubmed: 23194203
Crit Care. 2016 Sep 08;20:285
pubmed: 27604350
Br J Anaesth. 2003 Dec;91(6):781-6
pubmed: 14633744
J Neurosurg. 2001 Aug;95(2):222-32
pubmed: 11780891
Neurocrit Care. 2012 Apr;16(2):258-66
pubmed: 21964774
Neurosurgery. 2019 Jul 1;85(1):E75-E82
pubmed: 30476233
Neurotrauma Rep. 2020 Nov 06;1(1):157-168
pubmed: 33274344
J Neurosurg. 2014 Jun;120(6):1451-7
pubmed: 24745709
J Neurotrauma. 2021 Feb 15;38(4):506-512
pubmed: 32611275
Am J Physiol Renal Physiol. 2009 Jun;296(6):F1396-404
pubmed: 19297454
Can J Neurol Sci. 2020 Jul;47(4):551-556
pubmed: 32174295
Crit Care Med. 2012 Aug;40(8):2456-63
pubmed: 22622398
J Neurosci. 2001 May 1;21(9):3045-51
pubmed: 11312289
J Neurotrauma. 2018 Dec 1;35(23):2803-2811
pubmed: 29978744
J Clin Monit Comput. 2021 Aug;35(4):711-722
pubmed: 32418148
Neurocrit Care. 2005;2(1):83-95
pubmed: 16174975
J Neurotrauma. 2012 Apr 10;29(6):1105-10
pubmed: 22182405
Anesthesiology. 1990 Sep;73(3):404-9
pubmed: 2118315